Xeris Biopharma Holdings, Inc. (XERS) Profit Margins
Over the twelve months to 2026-06-30, Xeris Biopharma Holdings, Inc. (XERS) had gross margin 86.6%, operating margin 10.9%, net margin -5.1%, free cash flow margin 16.6%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XERSXeris Biopharma Holdings, Inc.Follow XERS — free
—
Price chart with a free account
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Gross margin | 73.1% | 79.5% | 82.5% | 81.9% | 85.4% | 86.6% | |
| Operating margin | -232.2% | -74.3% | -26.8% | -16.6% | 8.5% | 10.9% | |
| Net margin | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% | -5.1% | |
| FCF margin | -194.8% | -93.8% | -30.1% | -18.6% | 9.6% | 16.6% |
USD millions · SEC XBRL
Xeris Biopharma Holdings, Inc. — questions
- What is Xeris Biopharma Holdings, Inc.'s gross margin?
- 86.6% over the twelve months to 2026-06-30.
- What is Xeris Biopharma Holdings, Inc.'s operating margin?
- 10.9% over the twelve months to 2026-06-30.
- What is Xeris Biopharma Holdings, Inc.'s net profit margin?
- -5.1% over the twelve months to 2026-06-30.
Every figure on this page comes from Xeris Biopharma Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.